chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Hyperhidrosis, Pyrexia
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (Profuse sweating), PYREXIA (Very high fever of 103F to 104F), CHILLS (Bad chills/ rigours at nights), VOMITING (Vomiting) and HEADACHE (Headache) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030A21A and 021B21A) for COVID-19 vaccination. No medical history was provided by reporter. Concomitant products included COBICISTAT, ELVITEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE FUMARATE (GENVOYA), CYANOCOBALAMIN (VIT B 12) and TESTOSTERONE for an unknown indication. On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 29-Apr-2021, the patient experienced HYPERHIDROSIS (Profuse sweating), PYREXIA (Very high fever of 103F to 104F), CHILLS (Bad chills/ rigours at nights), VOMITING (Vomiting) and HEADACHE (Headache). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, HYPERHIDROSIS (Profuse sweating), PYREXIA (Very high fever of 103F to 104F), CHILLS (Bad chills/ rigours at nights), VOMITING (Vomiting) and HEADACHE (Headache) had resolved.    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Apr-2021, Body temperature: 103 to 104 (High) 103F to 104F. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. After receiving paracetamol it took 6 days for the symptoms to disappear completely. The patient received both scheduled doses of mRNA-1273 prior to the events therefore, action taken with the drug in response to the events was not applicable. This case was linked to MOD-2021-102002 (E2B Linked Report).; Sender's Comments: MOD-2021-102002:Dose1 case.
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (Profuse sweating), PYREXIA (Very high fever of 103F to 104F), CHILLS (Bad chills/ rigours at nights), VOMITING (Vomiting) and HEADACHE (Headache) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030A21A and 021B21A) for COVID-19 vaccination. No medical history was provided by reporter. Concomitant products included COBICISTAT, ELVITEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE FUMARATE (GENVOYA), CYANOCOBALAMIN (VIT B 12) and TESTOSTERONE for an unknown indication. On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 29-Apr-2021, the patient experienced HYPERHIDROSIS (Profuse sweating), PYREXIA (Very high fever of 103F to 104F), CHILLS (Bad chills/ rigours at nights), VOMITING (Vomiting) and HEADACHE (Headache). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, HYPERHIDROSIS (Profuse sweating), PYREXIA (Very high fever of 103F to 104F), CHILLS (Bad chills/ rigours at nights), VOMITING (Vomiting) and HEADACHE (Headache) had resolved.    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Apr-2021, Body temperature: 103 to 104 (High) 103F to 104F. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. After receiving paracetamol it took 6 days for the symptoms to disappear completely. The patient received both scheduled doses of mRNA-1273 prior to the events therefore, action taken with the drug in response to the events was not applicable. This case was linked to MOD-2021-102002 (E2B Linked Report).; Sender's Comments: MOD-2021-102002:Dose1 case.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Intestinal resection, Pain in extremity, Stoma site rash
Clinical narrative: stoma broke out; sore arm; This spontaneous case was reported by a physician and describes the occurrence of STOMA SITE RASH (stoma broke out) and PAIN IN EXTREMITY (sore arm) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.    The patient's past medical history included Depression, COVID-19 and Intestinal resection in 2018.   On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate Free. On an unknown date, ADALIMUMAB (HUMIRA) (unknown route) dosage was changed to Citrate free. On an unknown date, the patient experienced STOMA SITE RASH (stoma broke out) and PAIN IN EXTREMITY (sore arm). At the time of the report, STOMA SITE RASH (stoma broke out) had resolved and PAIN IN EXTREMITY (sore arm) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2018, Intestinal resection: (Inconclusive) Intestinal resection Done in 2018..     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. Treatment information was not reported. Action taken with mRNA-1273 in response to the event was not applicable.   Reporter did not allow further contact
Sex: U
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: Swollen lymph nodes; This spontaneous case was reported by a consumer and describes the occurrence of LYMPHADENOPATHY (Swollen lymph nodes) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.  On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced LYMPHADENOPATHY (Swollen lymph nodes). At the time of the report, LYMPHADENOPATHY (Swollen lymph nodes) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   Reporter/Patient was irritated with being on hold for a long time and was not cooperative in answering questions though did provide a phone number.  Treatment of events was not reported. Concomitant medication use was not provided by the reporter.
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Herpes zoster, Vaccination site erythema
Clinical narrative: Fatigue; Red spot under Covid vaccine injection site; Shingles; This spontaneous case was reported by a physician and describes the occurrence of HERPES ZOSTER (Shingles), FATIGUE (Fatigue) and VACCINATION SITE ERYTHEMA (Red spot under Covid vaccine injection site) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. and ADALIMUMAB (HUMIRA) (unknown route) at an unspecified dose. In October 2020, the patient experienced HERPES ZOSTER (Shingles). On an unknown date, the patient experienced FATIGUE (Fatigue) and VACCINATION SITE ERYTHEMA (Red spot under Covid vaccine injection site). At the time of the report, HERPES ZOSTER (Shingles) had resolved and FATIGUE (Fatigue) and VACCINATION SITE ERYTHEMA (Red spot under Covid vaccine injection site) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment or concomitant medications were reported.
Age: 81.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site mass, Vaccination site pain, Vaccination site warmth
Clinical narrative: Area below injection site is warm; lump below injection site; Area below injection site is sore; huge bright red welt below injection site on side of bicep; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Area below injection site is warm), VACCINATION SITE MASS (lump below injection site), VACCINATION SITE PAIN (Area below injection site is sore) and VACCINATION SITE ERYTHEMA (huge bright red welt below injection site on side of bicep) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included Spiriva                                                        bronchial condition and Vitamins                                                       supplement for an unknown indication.    On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Apr-2021, the patient experienced VACCINATION SITE WARMTH (Area below injection site is warm), VACCINATION SITE MASS (lump below injection site), VACCINATION SITE PAIN (Area below injection site is sore) and VACCINATION SITE ERYTHEMA (huge bright red welt below injection site on side of bicep). At the time of the report, VACCINATION SITE WARMTH (Area below injection site is warm), VACCINATION SITE MASS (lump below injection site), VACCINATION SITE PAIN (Area below injection site is sore) and VACCINATION SITE ERYTHEMA (huge bright red welt below injection site on side of bicep) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (soreness in his arm) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (soreness in his arm). At the time of the report, PAIN IN EXTREMITY (soreness in his arm) had resolved. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. Concomitant medications were not reported. No treatment information was provided by the reporter. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Sex: F
Vaccine: COVID19
Symptoms: Rash, Skin reaction
Clinical narrative: Rash on her arms; Skin reaction; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 29-Apr-2021 and was forwarded to Moderna on 29-Apr-2021.    This spontaneous case was reported by a consumer and describes the occurrence of SKIN REACTION (Skin reaction) and RASH (Rash on her arms) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SKIN REACTION (Skin reaction) and RASH (Rash on her arms). At the time of the report, SKIN REACTION (Skin reaction) and RASH (Rash on her arms) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications taken by the patient were not provided. Treatment information was not provided.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site pruritus, Vaccination site reaction
Clinical narrative: red, itchy, round area at injection site; red, itchy, round area at injection site; red, itchy, round area at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE REACTION (red, itchy, round area at injection site), VACCINATION SITE PRURITUS (red, itchy, round area at injection site) and VACCINATION SITE ERYTHEMA (red, itchy, round area at injection site) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 010M20A and 012L20A) for COVID-19 vaccination.     No Medical History Information was reported.  Concomitant products included CLONAZEPAM for Anxiety, MULTIVITAMINS [VITAMINS NOS] for an unknown indication.   On 07-Jan-2021 at 11:20 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021 at 10:20 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 04-Feb-2021, the patient experienced VACCINATION SITE REACTION (red, itchy, round area at injection site), VACCINATION SITE PRURITUS (red, itchy, round area at injection site) and VACCINATION SITE ERYTHEMA (red, itchy, round area at injection site). The patient was treated with CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) for Vaccination site pruritus, at an unspecified dose and frequency. On 08-Feb-2021, VACCINATION SITE REACTION (red, itchy, round area at injection site), VACCINATION SITE PRURITUS (red, itchy, round area at injection site) and VACCINATION SITE ERYTHEMA (red, itchy, round area at injection site) had resolved.            Action taken with mRNA-1273 in response to the event was not applicable.    This case was linked to US-MODERNATX, INC.-MOD-2021-015523 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-015523:First Dose
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Pain in extremity, Pyrexia
Clinical narrative: Sore arm; Slight temperature; chills; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (Sore arm), PYREXIA (Slight temperature) and CHILLS (chills) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 012M20A and 025L20A) for COVID-19 vaccination.     Concurrent medical conditions included Food allergy (MSG), Blood pressure high, Arrhythmia, Diverticulitis and Anemia.   On 12-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Feb-2021, the patient experienced PAIN IN EXTREMITY (Sore arm), PYREXIA (Slight temperature) and CHILLS (chills). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 15-Mar-2021, CHILLS (chills) had resolved. At the time of the report, PAIN IN EXTREMITY (Sore arm) and PYREXIA (Slight temperature) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication reported. treatment to the event given as rest , fluid drink.  Action taken with mRNA-1273 in response to the events was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 03-Mar-2021: Patient demographic details, medical history, product lot/ batch no and event stop date of chill  was updated from not recovered to recovered..
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Headache
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (she was dizzy on 2nd day) and HEADACHE (she having headaches and so forth and she is still getting some but  it might be allergies) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Sinusitis since an unknown date. Concurrent medical conditions included Allergy (Bad Allergies).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DIZZINESS (she was dizzy on 2nd day) and HEADACHE (she having headaches and so forth and she is still getting some but it might be allergies). At the time of the report, DIZZINESS (she was dizzy on 2nd day) and HEADACHE (she having headaches and so forth and she is still getting some but it might be allergies) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Treatment medications were provided No Concomitant medications were provided
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Circumstance or information capable of leading to medication error, Dizziness, Headache, Hypersensitivity, Sinus disorder
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (she was dizzy on 2nd day) and HEADACHE (she having headaches and so forth and she is still getting some but  it might be allergies) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Sinusitis since an unknown date. Concurrent medical conditions included Allergy (Bad Allergies).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DIZZINESS (she was dizzy on 2nd day) and HEADACHE (she having headaches and so forth and she is still getting some but it might be allergies). At the time of the report, DIZZINESS (she was dizzy on 2nd day) and HEADACHE (she having headaches and so forth and she is still getting some but it might be allergies) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Treatment medications were provided No Concomitant medications were provided
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Mass, Mood altered, Nasopharyngitis, Pruritus, Pyrexia
Clinical narrative: hives; cold; bumps that are spreading; very very sleepy; horrible experience; itching; bumps that are spreading; fever; rashy; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (hives), NASOPHARYNGITIS (cold), SKIN MASS (bumps that are spreading), SOMNOLENCE (very very sleepy) and MOOD ALTERED (horrible experience) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044B21) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included CHOLESTEROL, CYANOCOBALAMIN (VITAMIN B12 [CYANOCOBALAMIN]), COLECALCIFEROL (VITAMIN D [COLECALCIFEROL]), ASCORBIC ACID, ROSA CANINA FRUIT (VITAMIN C & ROSEHIP), GARLIC [ALLIUM SATIVUM] and IRON for an unknown indication.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced URTICARIA (hives), NASOPHARYNGITIS (cold), SKIN MASS (bumps that are spreading), SOMNOLENCE (very very sleepy), MOOD ALTERED (horrible experience), PRURITUS (itching), MASS (bumps that are spreading), PYREXIA (fever) and RASH (rashy). At the time of the report, URTICARIA (hives), NASOPHARYNGITIS (cold), SKIN MASS (bumps that are spreading), SOMNOLENCE (very very sleepy), MOOD ALTERED (horrible experience), PRURITUS (itching), MASS (bumps that are spreading), PYREXIA (fever) and RASH (rashy) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information were reported. Concomitant medications includes hormone medications.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Skin mass, Somnolence, Urticaria
Clinical narrative: hives; cold; bumps that are spreading; very very sleepy; horrible experience; itching; bumps that are spreading; fever; rashy; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (hives), NASOPHARYNGITIS (cold), SKIN MASS (bumps that are spreading), SOMNOLENCE (very very sleepy) and MOOD ALTERED (horrible experience) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044B21) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included CHOLESTEROL, CYANOCOBALAMIN (VITAMIN B12 [CYANOCOBALAMIN]), COLECALCIFEROL (VITAMIN D [COLECALCIFEROL]), ASCORBIC ACID, ROSA CANINA FRUIT (VITAMIN C & ROSEHIP), GARLIC [ALLIUM SATIVUM] and IRON for an unknown indication.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced URTICARIA (hives), NASOPHARYNGITIS (cold), SKIN MASS (bumps that are spreading), SOMNOLENCE (very very sleepy), MOOD ALTERED (horrible experience), PRURITUS (itching), MASS (bumps that are spreading), PYREXIA (fever) and RASH (rashy). At the time of the report, URTICARIA (hives), NASOPHARYNGITIS (cold), SKIN MASS (bumps that are spreading), SOMNOLENCE (very very sleepy), MOOD ALTERED (horrible experience), PRURITUS (itching), MASS (bumps that are spreading), PYREXIA (fever) and RASH (rashy) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information were reported. Concomitant medications includes hormone medications.
Sex: U
Vaccine: COVID19
Symptoms: Facial pain
Clinical narrative: extreme face pain; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of FACIAL PAIN (extreme face pain) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 21-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced FACIAL PAIN (extreme face pain). At the time of the report, FACIAL PAIN (extreme face pain) outcome was unknown.            Concomitant product use was not provided by the reporter. Treatment information was not provided.
Sex: U
Vaccine: COVID19
Symptoms: Facial pain
Clinical narrative: Extreme face pain; This spontaneous case was reported by a consumer and describes the occurrence of FACIAL PAIN (Extreme face pain) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 21-Apr-2021, the patient experienced FACIAL PAIN (Extreme face pain). At the time of the report, FACIAL PAIN (Extreme face pain) outcome was unknown. Second dose          No treatment information provided.   This case was linked to MOD-2021-102092 (Patient Link).
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Neck pain
Clinical narrative: hip pain/shoulder pain; Neck pain; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (hip pain/shoulder pain) and NECK PAIN (Neck pain) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (hip pain/shoulder pain) and NECK PAIN (Neck pain). At the time of the report, ARTHRALGIA (hip pain/shoulder pain) and NECK PAIN (Neck pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was provided. No treatment Information was provided.  The patient had hip, shoulder and neck pain and believes it was from the Modrna vaccine.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pruritus, Pyrexia, Rash
Clinical narrative: 102.6 fever/103.6 fever; something on my arm where the vaccine went in like a birthmark or something. it is elevated; Itching; Hives; chills; Tiredness; rash on my face and arm; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (chills), FATIGUE (Tiredness), RASH (rash on my face and arm), PYREXIA (102.6 fever/103.6 fever) and VACCINATION SITE SWELLING (something on my arm where the vaccine went in like a birthmark or something. it is elevated) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028A21A and 012A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was reported. No concomitant medication was reported.  The patient's past medical history included Cataract operation from November 2020 to December 2020. Concomitant products included CALCIUM ASCORBATE (VITAMIN C [CALCIUM ASCORBATE]), MULTI VITAMIN & MINERAL and KERATIN for an unknown indication.   On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced CHILLS (chills), FATIGUE (Tiredness), RASH (rash on my face and arm), PYREXIA (102.6 fever/103.6 fever), VACCINATION SITE SWELLING (something on my arm where the vaccine went in like a birthmark or something. it is elevated), PRURITUS (Itching) and URTICARIA (Hives). The patient was treated with PARACETAMOL (TYLENOL) for Fever, at a dose of 2 UNK. At the time of the report, CHILLS (chills), FATIGUE (Tiredness), VACCINATION SITE SWELLING (something on my arm where the vaccine went in like a birthmark or something. it is elevated), PRURITUS (Itching) and URTICARIA (Hives) outcome was unknown, RASH (rash on my face and arm) had not resolved and PYREXIA (102.6 fever/103.6 fever) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2020, SARS-CoV-2 test: negative (Negative) Negative.         This case was linked to MOD-2021-036902, MOD-2021-036902 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 22-Jun-2021: Follow up information received on 22-JUN-2021 and does not contain any new information
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, Urticaria, Vaccination site swelling
Clinical narrative: 102.6 fever/103.6 fever; something on my arm where the vaccine went in like a birthmark or something. it is elevated; Itching; Hives; chills; Tiredness; rash on my face and arm; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (chills), FATIGUE (Tiredness), RASH (rash on my face and arm), PYREXIA (102.6 fever/103.6 fever) and VACCINATION SITE SWELLING (something on my arm where the vaccine went in like a birthmark or something. it is elevated) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028A21A and 012A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was reported. No concomitant medication was reported.  The patient's past medical history included Cataract operation from November 2020 to December 2020. Concomitant products included CALCIUM ASCORBATE (VITAMIN C [CALCIUM ASCORBATE]), MULTI VITAMIN & MINERAL and KERATIN for an unknown indication.   On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced CHILLS (chills), FATIGUE (Tiredness), RASH (rash on my face and arm), PYREXIA (102.6 fever/103.6 fever), VACCINATION SITE SWELLING (something on my arm where the vaccine went in like a birthmark or something. it is elevated), PRURITUS (Itching) and URTICARIA (Hives). The patient was treated with PARACETAMOL (TYLENOL) for Fever, at a dose of 2 UNK. At the time of the report, CHILLS (chills), FATIGUE (Tiredness), VACCINATION SITE SWELLING (something on my arm where the vaccine went in like a birthmark or something. it is elevated), PRURITUS (Itching) and URTICARIA (Hives) outcome was unknown, RASH (rash on my face and arm) had not resolved and PYREXIA (102.6 fever/103.6 fever) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2020, SARS-CoV-2 test: negative (Negative) Negative.         This case was linked to MOD-2021-036902, MOD-2021-036902 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 22-Jun-2021: Follow up information received on 22-JUN-2021 and does not contain any new information
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of RASH (red large rash to arm) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 03721B) for COVID-19 vaccination. No Medical History information was reported. On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Apr-2021, the patient experienced RASH (red large rash to arm). On 27-Apr-2021, RASH (red large rash to arm) had resolved. Not Provided. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. No concomitant medications were provided. No treatment details were provided.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Hypersomnia
Clinical narrative: Put down for 2 days, Slept for 12 hours straight; This spontaneous case was reported by an other health care professional and describes the occurrence of HYPERSOMNIA (Put down for 2 days, Slept for 12 hours straight) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HYPERSOMNIA (Put down for 2 days, Slept for 12 hours straight). At the time of the report, HYPERSOMNIA (Put down for 2 days, Slept for 12 hours straight) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications or treatments were provided.
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Headache, Pain, Pyrexia
Clinical narrative: Body aches; Fever upto 101.3; Headaches; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Body aches), PYREXIA (Fever upto 101.3) and HEADACHE (Headaches) in a 34-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 048A21A and 030M20A) for COVID-19 vaccination.     Concurrent medical conditions included Asthma since 20-Jul-1990.   On 18-Feb-2021 at 2:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Mar-2021, the patient experienced PAIN (Body aches), PYREXIA (Fever upto 101.3) and HEADACHE (Headaches). On 21-Mar-2021, PAIN (Body aches), PYREXIA (Fever upto 101.3) and HEADACHE (Headaches) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 101.3 °F.         No concomitant medications provided. After the second vaccine, the patient experienced a fever up to 101.3, body aches, and headaches. After 24 hours of the symptoms, he took Tylenol and it was better within another 24 hours.   This case was linked to MOD-2021-018246 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: shingles; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (shingles) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 15-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HERPES ZOSTER (shingles). At the time of the report, HERPES ZOSTER (shingles) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No laboratory details were  provided.  No treatment medications were reported.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Pain in extremity
Clinical narrative: This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (sore arm (pain in arm)) and ABDOMINAL PAIN (abdominal pain) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. Co-suspect product included non-company product OBETICHOLIC ACID (OCALIVA) for Primary biliary cirrhosis. Previously administered products included for an unreported indication: PENICILLIN NOS since an unknown date. Concurrent medical conditions included Primary biliary cholangitis and Penicillin allergy. Concomitant products included IBUPROFEN for an unknown indication. In 2018, the patient started OBETICHOLIC ACID (OCALIVA) (Oral) 5 mg once a day. On 02-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Apr-2021, the patient experienced PAIN IN EXTREMITY (sore arm (pain in arm)) and ABDOMINAL PAIN (abdominal pain). In April 2021, PAIN IN EXTREMITY (sore arm (pain in arm)) had resolved. At the time of the report, ABDOMINAL PAIN (abdominal pain) had not resolved. No treatment information provided. Action taken with mRNA-1273 in response to the events was not applicable.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Blood mercury, Burning sensation, Rash macular, Skin lesion inflammation, Swelling
Clinical narrative: This spontaneous case was reported by an other health care professional and describes the occurrence of RASH MACULAR (big blotchy and red raised welts and hives), SWELLING (big blotchy and red raised welts and hives), URTICARIA (big blotchy and red raised welts and hives), SKIN LESION INFLAMMATION (red and inflamed bumps with tissue swelling,spread to buttock and down knees and to forearm) and BURNING SENSATION (itching and burning) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001A21A) for COVID-19 vaccination. Concomitant products included ACETYLSALICYLIC ACID (BABY ASPIRIN) for an unknown indication. On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, the patient experienced RASH MACULAR (big blotchy and red raised welts and hives), SWELLING (big blotchy and red raised welts and hives), URTICARIA (big blotchy and red raised welts and hives) and SKIN LESION INFLAMMATION (red and inflamed bumps with tissue swelling,spread to buttock and down knees and to forearm). On an unknown date, the patient experienced BURNING SENSATION (itching and burning). The patient was treated with HYDROCORTISONE ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, RASH MACULAR (big blotchy and red raised welts and hives), SWELLING (big blotchy and red raised welts and hives), URTICARIA (big blotchy and red raised welts and hives), SKIN LESION INFLAMMATION (red and inflamed bumps with tissue swelling,spread to buttock and down knees and to forearm) and BURNING SENSATION (itching and burning) outcome was unknown.   DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood mercury: high (High) High. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. Concomitant medications included Anti-thyroid medications.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: This spontaneous case was reported by an other health care professional and describes the occurrence of RASH MACULAR (big blotchy and red raised welts and hives), SWELLING (big blotchy and red raised welts and hives), URTICARIA (big blotchy and red raised welts and hives), SKIN LESION INFLAMMATION (red and inflamed bumps with tissue swelling,spread to buttock and down knees and to forearm) and BURNING SENSATION (itching and burning) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001A21A) for COVID-19 vaccination. Concomitant products included ACETYLSALICYLIC ACID (BABY ASPIRIN) for an unknown indication. On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, the patient experienced RASH MACULAR (big blotchy and red raised welts and hives), SWELLING (big blotchy and red raised welts and hives), URTICARIA (big blotchy and red raised welts and hives) and SKIN LESION INFLAMMATION (red and inflamed bumps with tissue swelling,spread to buttock and down knees and to forearm). On an unknown date, the patient experienced BURNING SENSATION (itching and burning). The patient was treated with HYDROCORTISONE ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, RASH MACULAR (big blotchy and red raised welts and hives), SWELLING (big blotchy and red raised welts and hives), URTICARIA (big blotchy and red raised welts and hives), SKIN LESION INFLAMMATION (red and inflamed bumps with tissue swelling,spread to buttock and down knees and to forearm) and BURNING SENSATION (itching and burning) outcome was unknown.   DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood mercury: high (High) High. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. Concomitant medications included Anti-thyroid medications.
Age: 58.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Vaccination site erythema, Vaccination site pruritus, Vaccination site swelling
Clinical narrative: Vaccination site pruritus; Injection site redness; injection site swelling; This spontaneous case was reported by a physician and describes the occurrence of VACCINATION SITE PRURITUS (Vaccination site pruritus), VACCINATION SITE ERYTHEMA (Injection site redness) and VACCINATION SITE SWELLING (injection site swelling) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    No medical history was reported by the reporter.    In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to at an unspecified dose. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) Dosage #2 and ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In January 2021, the patient experienced VACCINATION SITE PRURITUS (Vaccination site pruritus), VACCINATION SITE ERYTHEMA (Injection site redness) and VACCINATION SITE SWELLING (injection site swelling). At the time of the report, VACCINATION SITE PRURITUS (Vaccination site pruritus) had resolved and VACCINATION SITE ERYTHEMA (Injection site redness) and VACCINATION SITE SWELLING (injection site swelling) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Age: 24.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Nausea
Clinical narrative: nausea; fever-like chills with no temperature; This spontaneous case was reported by a non-health professional and describes the occurrence of CHILLS (fever-like chills with no temperature) and NAUSEA (nausea) in a 24-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 29-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1. On 30-Apr-2021, the patient experienced CHILLS (fever-like chills with no temperature). On an unknown date, the patient experienced NAUSEA (nausea). At the time of the report, CHILLS (fever-like chills with no temperature) and NAUSEA (nausea) outcome was unknown.            No relevant concomitant medications were reported. Treatment Medications were not provided by the reporter.
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Influenza like illness, Pain in extremity, Pyrexia
Clinical narrative: Extremely tired; Feverish; Flu-like symptoms; Pain in arm; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu-like symptoms), PAIN IN EXTREMITY (Pain in arm), FATIGUE (Extremely tired) and PYREXIA (Feverish) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     no medical history was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (Flu-like symptoms), PAIN IN EXTREMITY (Pain in arm), FATIGUE (Extremely tired) and PYREXIA (Feverish). At the time of the report, INFLUENZA LIKE ILLNESS (Flu-like symptoms), PAIN IN EXTREMITY (Pain in arm) and PYREXIA (Feverish) had resolved and FATIGUE (Extremely tired) had not resolved.            No treatment and concomitant medication reported.   This case was linked to MOD-2021-037243 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 16-Jun-2021: Therapy details were added.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Decreased appetite, Disturbance in attention, Dyspnoea, Facial pain
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of MUSCULAR WEAKNESS (weakness in legs), FACIAL PAIN (facial pain), PAIN IN JAW (pain in jaw), DISTURBANCE IN ATTENTION (disturbance in attention) and COUGH (cough) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product TREPROSTINIL SODIUM (TYVASO) inhalation gas for Secondary pulmonary arterial hypertension.    The patient's past medical history included Secondary pulmonary arterial hypertension. Concurrent medical conditions included Pulmonary arterial hypertension.   On 13-Oct-2020, the patient started TREPROSTINIL SODIUM (TYVASO) (Nasal) 60-120 microgram, qid, inhalation. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MUSCULAR WEAKNESS (weakness in legs), FACIAL PAIN (facial pain), PAIN IN JAW (pain in jaw), DISTURBANCE IN ATTENTION (disturbance in attention), COUGH (cough), DYSPNOEA (dyspnoea), DECREASED APPETITE (decreased appetite), VACCINATION SITE ERYTHEMA (redness at covid vaccine injection site) and FATIGUE (fatigue). At the time of the report, MUSCULAR WEAKNESS (weakness in legs), FACIAL PAIN (facial pain), PAIN IN JAW (pain in jaw), DISTURBANCE IN ATTENTION (disturbance in attention), COUGH (cough), DYSPNOEA (dyspnoea), VACCINATION SITE ERYTHEMA (redness at covid vaccine injection site) and FATIGUE (fatigue) outcome was unknown and DECREASED APPETITE (decreased appetite) had resolved.            No treatment information was provided.  The action taken with mRNA-1273 in response to the event was not applicable.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Muscular weakness, Pain in jaw, Vaccination site erythema
Clinical narrative: This spontaneous case was reported by a consumer and describes the occurrence of MUSCULAR WEAKNESS (weakness in legs), FACIAL PAIN (facial pain), PAIN IN JAW (pain in jaw), DISTURBANCE IN ATTENTION (disturbance in attention) and COUGH (cough) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product TREPROSTINIL SODIUM (TYVASO) inhalation gas for Secondary pulmonary arterial hypertension.    The patient's past medical history included Secondary pulmonary arterial hypertension. Concurrent medical conditions included Pulmonary arterial hypertension.   On 13-Oct-2020, the patient started TREPROSTINIL SODIUM (TYVASO) (Nasal) 60-120 microgram, qid, inhalation. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MUSCULAR WEAKNESS (weakness in legs), FACIAL PAIN (facial pain), PAIN IN JAW (pain in jaw), DISTURBANCE IN ATTENTION (disturbance in attention), COUGH (cough), DYSPNOEA (dyspnoea), DECREASED APPETITE (decreased appetite), VACCINATION SITE ERYTHEMA (redness at covid vaccine injection site) and FATIGUE (fatigue). At the time of the report, MUSCULAR WEAKNESS (weakness in legs), FACIAL PAIN (facial pain), PAIN IN JAW (pain in jaw), DISTURBANCE IN ATTENTION (disturbance in attention), COUGH (cough), DYSPNOEA (dyspnoea), VACCINATION SITE ERYTHEMA (redness at covid vaccine injection site) and FATIGUE (fatigue) outcome was unknown and DECREASED APPETITE (decreased appetite) had resolved.            No treatment information was provided.  The action taken with mRNA-1273 in response to the event was not applicable.